Product Name	phospho-PI3 Kinase p110 beta (Ser1070)
Chinese Name	磷酸化磷脂酰肌醇激酶（PI3Kβ）抗体
Alias	PI3-kinase p110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; Pik3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.
literatures	Specific References  (39)     |     SL6417R has been referenced in 39 publications. [IF=17.337] Yun Chen. et al. Extracellular vesicles derived from Akkermansia muciniphila promote placentation and mitigate preeclampsia in a mouse model. J EXTRACELL VESICLES. 2023 May;12(5):12328  WB ;  Mouse，Human.   PubMed:37165987 [IF=11.508] Qinyu Ma. et al. Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling. Bone Res. 2021 Jan;9(1):1-12  WB ;  Mouse.   PubMed:33431863 [IF=9.918] Yanhong Pei. et al. Bone marrow mesenchymal stem cells loaded into hydrogel/nanofiber composite scaffolds ameliorate ischemic brain injury. MATER TODAY ADV. 2023 Mar;17:100349  WB ;  Rat.   PubMed:10.1016/j.mtadv.2023.100349 [IF=5.988] Dongfang Lv. et al. Mailuoshutong pill for varicocele-associated male infertility-Phytochemical characterisation and multitarget mechanism.. FRONT PHARMACOL. 2022 Sep;13:961011-961011  WB ;  Rat.   PubMed:36160417 [IF=5.884] Xiya Guo. et al. The ALK1‑Smad1/5‑ID1 pathway participates in tumour angiogenesis induced by low‑dose photodynamic therapy. INT J ONCOL. 2023 Apr;62(4):1-16  WB ;  Human.   PubMed:36928315 [IF=5.714] Chenglin Li. et al. Ranitidine as an adjuvant regulates macrophage polarization and activates CTLs through the PI3K-Akt2 signaling pathway. INT IMMUNOPHARMACOL. 2023 Mar;116:109729  WB ;  Mouse.   PubMed:10.1016/j.intimp.2023.109729 [IF=5.561] Xinyang Fan. et al. CEBPA-Regulated Expression of SOCS1 Suppresses Milk Protein Synthesis through mTOR and JAK2-STAT5 Signaling Pathways in Buffalo Mammary Epithelial Cells. FOODS. 2023 Jan;12(4):708  WB ;  Bovine.   PubMed:36832783 [IF=5.546] Liu X et al. miR‐34a/c induce caprine endometrial epithelial cell apoptosis by regulating circ‐8073/CEP55 via the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. J Cell Physiol. 2020 Dec;235(12):10051-10067.  WB ;  Goat.   PubMed:32474960 [IF=5.546] Liu X et al. miR‐34a/c induce caprine endometrial epithelial cell apoptosis by regulating circ‐8073/CEP55 via the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. J Cell Physiol . 2020 Dec;235(12):10051-10067.  WB ;  Goat.   PubMed:32474960 [IF=5.31] Li Ma. et al. Effect of MiR-100-5p on proliferation and apoptosis of goat endometrial stromal cell in vitro and embryo implantation in vivo. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2022 Apr 12  WB ;  Goat.   PubMed:35411593 [IF=5.253] Liu,et al.Slit2/Robo1 signaling is involved in angiogenesis of glomerular endothelial cells exposed to a diabetic-like environment.(2018) Angiogenesis. 21:237-249.  WB ;  Human.   PubMed:29299781 [IF=5.246] Yin Zhuang. et al. Exosomes Secreted by Nucleus Pulposus Stem Cells Derived From Degenerative Intervertebral Disc Exacerbate Annulus Fibrosus Cell Degradation via Let-7b-5p. Front Mol Biosci. 2021; 8: 766115  WB ;  Human.   PubMed:35111808 [IF=5.223] Li-You Chen. et al. Luteolin improves nephropathy in hyperglycemic rats through anti-oxidant, anti-inflammatory, and anti-apoptotic mechanisms. J FUNCT FOODS. 2023 Mar;102:105461  WB ;  Rat.   PubMed:10.1016/j.jff.2023.105461 [IF=5.223] Xinyang Fan. et al. MiR-190a regulates milk protein biosynthesis through the mTOR and JAK2–STAT5 signaling pathways by targeting PTHLH in buffalo mammary epithelial cells. J FUNCT FOODS. 2023 Mar;102:105451  WB ;  Bovine.   PubMed:10.1016/j.jff.2023.105451 [IF=5.201] Zhang Y et al. A Regulatory Circuit Orchestrated by Novel-miR-3880 Modulates Mammary Gland Development. Front Cell Dev Biol. 2020 Jun 16;8:383.  WB ;  Mouse&Goat.   PubMed:32656203 [IF=5.195] Yu Ma. et al. Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. J ETHNOPHARMACOL. 2023 Feb;302:115768  WB ;  Rat.   PubMed:36280016 [IF=5.195] Fei Chen. et al. Antitumor mechanism of kangliu pill on gliomas in mice through PI3K-Akt signaling pathway. J ETHNOPHARMACOL. 2023 Feb;:116252  WB ;  Human.   PubMed:36775078 [IF=4.868] Wang Z et al. Interaction between Endothelin-1 and Left Stellate Ganglion Activation: A Potential Mechanism of Malignant Ventricular Arrhythmia during Myocardial Ischemia. Oxid Med Cell Longev. 2019 May 12;2019:6508328.  WB ;  Dog.   PubMed:31214281 [IF=4.831] Chen Y et al. Epothilone B prevents lipopolysaccharide-induced inflammatory osteolysis through suppressing osteoclastogenesis via STAT3 signaling pathway. Aging (Albany NY). 2020 Jun 11;12(12):11698-11716.  WB ;  Mouse.   PubMed:32527985 [IF=4.711] Xiaoyu Sui. et al. hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway. CANCER MED-US. 2022 Oct;:  WB ;  Human.   PubMed:36305754 [IF=4.2] Li Li. et al. Regulation of TREM2 on BV2 inflammation through PI3K/AKT/mTOR pathway. BIOTECHNOL GENET ENG. 2023 Apr 26  WB ;  Mouse.   PubMed:37125903 [IF=4.145] Shaogeng Chen. et al. PHLDA3 activated by BARX2 transcription, suppresses the malignant development of esophageal squamous cell carcinoma by downregulating PI3K/AKT levels. EXP CELL RES. 2023 Mar;:113567  WB ;  Mouse.   PubMed:36965748 [IF=4.034] Siyuan Liu. et al. β-Hydroxybutyrate impairs the release of bovine neutrophil extracellular traps through inhibiting phosphoinositide 3-kinase–mediated nicotinamide adenine dinucleotide phosphate oxidase reactive oxygen species production. J Dairy Sci. 2022 Feb;:  WB ;  Cow.   PubMed:35123783 [IF=3.776] Tingting Zhao. et al. Yishen Huashi granule modulated lipid metabolism in diabetic nephropathy via PI3K/AKT/mTOR signaling pathways.. HELIYON. 2023 Mar;9(3):e14171-e14171  WB ;  Human.   PubMed:36938470 [IF=3.674] Qiao Wanchen. et al. Liensinine ameliorates ischemia–reperfusion-induced brain injury by inhibiting autophagy via PI3K/AKT signaling. FUNCT INTEGR GENOMIC. 2023 Jun;23(2):1-9  WB ;  Rat.   PubMed:37118322 [IF=3.616] Shugen Xu. et al. Effect of miR-21-3p on lung injury in rats with traumatic hemorrhagic shock resuscitated with sodium bicarbonate Ringer’s solution. ANN TRANSL MED. 2022 Dec; 10(24): 1331  WB ;  Rat.   PubMed:36660723 [IF=3.514] Li B et al. Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264. 7 macrophages.Cytokine. 2019 Jul;119:168-174.  WB ;  Mouse.   PubMed:30925325 [IF=3.448] Jin Y et al. miR‐496 remedies hypoxia reoxygenation–induced H9c2 cardiomyocyte apoptosis via Hook3‐targeted PI3k/Akt/mTOR signaling pathway activation. J Cell Biochem. 2019 Aug 22.  WB ;  Rat&Human.   PubMed:31436348 [IF=3.17] Yang RP et al. Pharmacological actions of neferine in the modulation of human platelet function. Eur J Pharmacol. 2019 Aug 21:172626.  WB ;  Human.   PubMed:31445013 [IF=3.15] Han Chen. et al. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway. Bmc Cancer. 2020 Dec;20(1):1-10  WB ;  Human.   PubMed:32891122
Product Type	Phosphorylated anti
Research Area	Tumour  Cell biology  immunology  Signal transduction  Cyclin  Kinases and Phosphatases
Immunogen Species	Rabbit
Clonality	Polyclonal
React Species	Human, Mouse, Rat,  (predicted: Chicken, Dog, Pig, Cow, Horse, Guinea Pig, )
Applications	WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （Paraffin sections need antigen repair） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
Theoretical molecular weight	110-123kDa
Cellular localization	The nucleus cytoplasmic
Form	Liquid
Concentration	1mg/ml
immunogen	KLH conjugated synthesised phosphopeptide derived from human PI3 Kinase p110 beta around the phosphorylation site of Ser1070: YR(p-S)
Lsotype	IgG
Purification	affinity purified by Protein A
Buffer Solution	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Attention	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed	PubMed
Product Detail	Phosphoinositide 3-kinases (PI 3-Ks) phosphorylate the 3’- OH position of the inositol ring of inositol lipids. They act as participants in signaling pathways that regulate cell growth by virtue of their activation in response to various mitogenic stimuli. PI 3-Ks are composed of a catalytic subunit, such as PI 3-kinase C2∫ (PIK3CB) and an adaptor subunit. PI 3-kinase C2∫ , also known as p110-∫, is a 1,070 amino acid protein that shares 42% identity with p110 of cow origin. It is expressed in several human and rodent cell lines. Studies predict that PI 3-kinase C2∫ has a role in modulating the formation and stability of å2B (ITGA2B)/∫3 (ITGB3) Integrin adhesion bonds, which are essential in shear force-induced platelet activation. Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2. Subunit: Heterodimer of a catalytic subunit PIK3CB and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interaction with PIK3R2 is required for nuclear localization and nuclear export. Part of a complex with PIK3R1 and PTEN. Binding to PTEN may antagonize the lipid kinase activity under normal growth conditions. Part of a complex involved in autophagosome formation composed of PIK3C3 and PIK3R4 (By similarity). Interacts with BECN1, ATG14 and RAB5A. Subcellular Location: Cytoplasm. Nucleus. Note=Interaction with PIK3R2 is required for nuclear localization and export. Tissue Specificity: Expressed ubiquitously. Similarity: Belongs to the PI3/PI4-kinase family. Contains 1 C2 PI3K-type domain. Contains 1 PI3K-ABD domain. Contains 1 PI3K-RBD domain. Contains 1 PI3K/PI4K domain. Contains 1 PIK helical domain. SWISS: P42338 Gene ID: 5291 Database links: Entrez Gene: 5291 Human Entrez Gene: 74769 Mouse Entrez Gene: 85243 Rat Omim: 602925 Human SwissProt: P42338 Human SwissProt: Q24JU2 Human SwissProt: Q3U4Q1 Mouse SwissProt: Q8BTI9 Mouse SwissProt: Q9Z1L0 Rat Unigene: 239818 Human Unigene: 213128 Mouse Unigene: 44268 Rat
Product Picture	Sample: Lane 1: Human MCF-7 cell lysates Lane 2: Human K562 cell lysates Primary: Anti-phospho-PI3 Kinase p110 beta (Ser1070) (SL6417R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 110-123 kD Observed band size: 110 kD Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta(Ser1070)) Polyclonal Antibody, Unconjugated (SL6417R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining. Tissue/cell: human colon carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-phospho-PI3 Kinase p110 beta(Ser1070) Polyclonal Antibody, Unconjugated (SL6417R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Paraformaldehyde-fixed, paraffin embedded (mouse kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta (Ser1070) ) Polyclonal Antibody, Unconjugated (SL6417R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (mouse colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta (Ser1070) ) Polyclonal Antibody, Unconjugated (SL6417R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta (Ser1070) ) Polyclonal Antibody, Unconjugated (SL6417R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta (Ser1070) ) Polyclonal Antibody, Unconjugated (SL6417R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3 Kinase p110 beta (Ser1070) ) Polyclonal Antibody, Unconjugated (SL6417R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Tissue/cell: human gastric carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-phospho-PI3 Kinase p110 beta(Ser1070) Polyclonal Antibody, Unconjugated (SL6417R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-phospho-PI3 Kinase p110 beta(Ser1070) Polyclonal Antibody, Unconjugated (SL6417R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-phospho-PI3 Kinase p110 beta(Ser1070) Polyclonal Antibody, Unconjugated (SL6417R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

Cartpieces

• 
• 1

  1Delete

• 
• 5

  5Delete

• 
• S

  SDelete

• 
• R

  RDelete

• 
• +

  +Delete

• 
• 3

  3Delete

• Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 4

  4Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• P

  PDelete

• 
• P

  PDelete

• 

• Delete

• 
• i

  iDelete

• 
• i

  iDelete

• Delete

• 
• 1

  1Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• Delete

• 
• 2

  2Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• Delete

• 
• -

  -Delete

• 
• -

  -Delete

• 
• 0

  0Delete

• Delete

• 
• t

  tDelete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• f

  fDelete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• 
• 4

  4Delete

• 
• $

  $Delete

• Delete

• 
• 0

  0Delete

• Delete

• Delete

• Delete

• 
• R

  RDelete

• 
• 5

  5Delete

• 
• A

  ADelete

Totalgoods,subtotals:￥Checkout